Controversies and future directions of ocular biomarkers in Alzheimer disease

Sally S. Ong; P. Murali Doraiswamy; Eleonora M. Lad

doi:10.1001/jamaneurol.2018.0602

Controversies and future directions of ocular biomarkers in Alzheimer disease

Sally S. Ong, P. Murali Doraiswamy, Eleonora M. Lad

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	650-651
Number of pages	2
Journal	JAMA Neurology
Volume	75
Issue number	6
DOIs	https://doi.org/10.1001/jamaneurol.2018.0602
State	Published - Jun 2018
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1001/jamaneurol.2018.0602

Cite this

@article{44905de8a4384562a25ecc40d9b60888,

title = "Controversies and future directions of ocular biomarkers in Alzheimer disease",

author = "Ong, {Sally S.} and {Murali Doraiswamy}, P. and Lad, {Eleonora M.}",

note = "Funding Information: reported receiving research grants and advisory fees from Avid/Lilly, Anthrotronix, Cure Alzheimer Foundation, Genomind, Neuronetrix, NeuroPro, Targacept, Cognoptix, Piramal, Sonexa, Neurocog Trials, Muses Lab, T3D Therapeutics, Holmusk, University of California, San Diego/Alzheimer's Disease Cooperative Study, University of Southern California, Forum Pharma, Avanir, Wrenn Trust, Hintsa performance, Crossings, Metabolomics, Postgraduate Press, Pfizer, and World Economic Forum and owning stock in Adverse Events Inc, Maxwell Health, Muses Lab, Evidation, and Anthrotronix. No other disclosures were reported. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2018",

month = jun,

doi = "10.1001/jamaneurol.2018.0602",

language = "English (US)",

volume = "75",

pages = "650--651",

journal = "JAMA Neurology",

issn = "2168-6149",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Controversies and future directions of ocular biomarkers in Alzheimer disease

AU - Ong, Sally S.

AU - Murali Doraiswamy, P.

AU - Lad, Eleonora M.

N1 - Funding Information: reported receiving research grants and advisory fees from Avid/Lilly, Anthrotronix, Cure Alzheimer Foundation, Genomind, Neuronetrix, NeuroPro, Targacept, Cognoptix, Piramal, Sonexa, Neurocog Trials, Muses Lab, T3D Therapeutics, Holmusk, University of California, San Diego/Alzheimer's Disease Cooperative Study, University of Southern California, Forum Pharma, Avanir, Wrenn Trust, Hintsa performance, Crossings, Metabolomics, Postgraduate Press, Pfizer, and World Economic Forum and owning stock in Adverse Events Inc, Maxwell Health, Muses Lab, Evidation, and Anthrotronix. No other disclosures were reported. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2018/6

Y1 - 2018/6

UR - http://www.scopus.com/inward/record.url?scp=85048707723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048707723&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2018.0602

DO - 10.1001/jamaneurol.2018.0602

M3 - Comment/debate

C2 - 29710250

AN - SCOPUS:85048707723

SN - 2168-6149

VL - 75

SP - 650

EP - 651

JO - JAMA Neurology

JF - JAMA Neurology

IS - 6

ER -

Controversies and future directions of ocular biomarkers in Alzheimer disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this